Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
ECB’s Philip Lane Warns Middle East Conflict Could Keep Inflation Elevated 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
U.S. Sanctions Iran’s Strait of Hormuz Authority as Global Oil Markets Face Turmoil 
UK Grocery Inflation Slows to 3.1% as Supermarket Price Pressures Ease in May 2026 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
Lam Research Expands AI-Powered Semiconductor Tools and Arizona Operations 
US Imposes Fresh Iran Oil Sanctions Despite Progress on Ceasefire Talks 
Dow Hits Record High as Healthcare and Consumer Stocks Lead Wall Street Rally 
Asian Stocks Rally as AI Boom and Iran Ceasefire Progress Lift Market Sentiment 
PDG Explores $1 Billion Sale of China Data Center Assets 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
Meta AI Push Could Add $26 Billion in Revenue by 2027, Wolfe Research Says 
South Korea Central Bank Holds Interest Rates Steady Amid Inflation Concerns 
Oil Prices Set for Sharp Weekly Losses as U.S.-Iran Ceasefire Hopes Ease Supply Concerns 
SpaceX IPO Hype Raises Questions as Many Major Stock Debuts Underperform Market 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
Samsung C&T attributed its first-quarter net profit surge of 55.8 percent to equity gains from its affiliate Samsung Biologics and profitable overseas projects.
The company, a construction affiliate of the Samsung Group, said in a regulatory filing that it had a net profit of 346.5 billion won for January to March, up from 222.4 billion won in the same period a year before.
Samsung C&T owns a 43.3 percent share in Samsung Biologics, a biopharmaceutical unit of Samsung Group.
The company claimed a first-quarter increase of 39.8 percent in its operating profit to 147 billion from 105 billion won in the same period last year.
However, Samsung C&T's revenue of 6.96 trillion won is a 5.4 percent dip from 7.35 trillion won last year. It attributed the drop to decreasing domestic consumption, and trading volume brought about by the COVID-19 situation, and for the completion of construction projects undertaken by the company.
Shares in Samsung C&T is up 3.3 percent to 97,000 won, outperforming KOSPI's gain of 0.89 percent gain.
"Increased equity gains from Samsung Biologics and profitable overseas projects boosted the first-quarter net profit," an official of Samsung C&T said.
